Items where authors include "Barrientos, JC"

Article

Barrientos, JC, Hillmen, P orcid.org/0000-0001-5617-4403, Salles, G et al. (8 more authors) (2020) No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma. ISSN 1042-8194

Solman, IG, Blum, LK, Hoh, HY et al. (11 more authors) (2020) Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia. Leukemia Research. 106432. p. 106432. ISSN 0145-2126

Ghia, P, Coutre, SE, Cheson, BD et al. (7 more authors) (2020) Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. Haematologica. ISSN 0390-6078

Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609

O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609

Barrientos, JC, Burger, JA, Byrd, JC et al. (5 more authors) (2019) Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia & Lymphoma, 60 (4). pp. 1000-1005. ISSN 1042-8194

Barrientos, JC, O'Brien, S, Brown, JR et al. (25 more authors) (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 18 (12). 803-813.e7. ISSN 2152-2650

Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924

Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971